Speetjens, F. M., Welters, M. J. P., Slingerland, M., van Poelgeest, M. I. E.
, de Vos van Steenwijk, P. J., Roozen, I., Boekestijn, S., Loof, N. M., Zom, G. G., Valentijn, A. R. P. M., Krebber, W.-J., Meeuwenoord, N. J., Janssen, C. A. H., Melief, C. J. M., van der Marel, G. A., Filippov, D. V., van der Burg, S. H., Gelderblom, H., & Ossendorp, F. (2022).
Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesions.
Journal for ImmunoTherapy of Cancer,
10(10), Article e005016.
https://doi.org/10.1136/jitc-2022-005016